Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
   
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  SWAN Knowledge Base
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Pathways
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Stockholm: Chlamydia Triggers Amyloid Plaques in Mice
22 July 2002. Stockholm. Chlamydia pneumoniae is an insidious intracellular bacterium to which almost the entire worldwide population has been exposed by age 70. It primarily causes inflammatory lung disease but has in the past decade been implicated in the development of atherosclerotic plaques. Yesterday at the 8th International Conference on Alzheimer’s Disease and Related Disorders, Brian Balin and colleagues at the Philadelphia College of Osteopathic Medicine presented data showing that chlamydia isolated from Alzheimer’s brain, cultured, and then sprayed into the noses of young wild-type BALB/c mice can cause progressive deposition of amyloid plaques, in essence creating a partial model of AD without using any transgenes. At 15 months, plaque load rises steeply, Balin said.

“We believe this could be a trigger mechanism for the pathology in AD,” said Balin. “People have been suspecting this for decades but could not find anything. It is very difficult to pinpoint an infectious cause for a progressive, chronic disease. We also believe that our isolation of chlamydia from the human AD brain and induction of pathology in normal mice is proof of principle that this can be a causative mechanism turning on pathology.”

Balin and colleagues identified the plaques with Aβ42 antibodies and thioflavin-S staining. They have not found neurofibrillary tangles in their mice, but are currently looking for tau accumulation and neuritic dystrophy in older animals. They also have not yet looked for behavioral deficits.

Interestingly, Balin and his colleagues found the bacterium primarily in microglia, astroglia, and perivascular macrophages, both in human and the mice. A poster on Wednesday examines pathways by which this organism can enter the brain after a respiratory tract infection, essentially suggesting that blood monocytes harboring the pathogen can penetrate the blood-brain barrier by altering tight junctions. Balin believes that chlamydia, which is known to upregulate the expression of proinflammatory cytokines, may induce amyloid pathology as a consequence of this glia-derived inflammation.

In 1998, these researchers reported in Medical Microbioloy and Immunology that of 50 brains of sporadic AD cases, 90 percent had chlamydia in their brains, whereas only five percent of the controls did. Since exposure is widespread, this begs the question which genetic host response factors may allow some people to shed the infection more effectively than others. These could be among genetic risk factors for some cases of sporadic AD, said Balin. For a start, Alan Hudson and colleagues at Wayne State University School of Medicine in Detroit, Michigan, tomorrow are presenting data suggesting that cultured human astrocytes are more easily infected with chlamydia if they are ApoE4 positive than if they carry the other ApoE alleles, and that ApoE4-positive samples of frontal and temporal cortex and hippocampus of AD brains had higher bacterial load than did samples carrying E2 or E3.-Gabrielle Strobel.

 
Comments on Related Papers
Related Paper: Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain.

Comment by:  Paul Coleman, ARF Advisor

Another organism linked to AD. Why has this not been seen before?

View all comments by Paul Coleman

Related Paper: Role of infection in Alzheimer's disease.

Comment by:  Paula Carnes
Submitted 23 July 2002 Posted 23 July 2002
  I recommend this paper
Comments on Related News
Related News: Chlamydia Update

Comment by:  Brian Balin
Submitted 7 April 2000 Posted 7 April 2000

This letter is in response to the recent article in Journal of Clinical Microbiology (38[2]:881-882, 2000) entitled "Failure to detect Chlamydia pneumoniae in brain sections of Alzheimer's Disease Patients" by Gieffers et al. Since we were the first to report on this issue (Balin, et al., 1998), I wanted to address how the present report differs quite substantially from that which we reported.

My comments are outlined below:

The recent report by Gieffers, et al. does not address our previous research findings using any of the same protocols with which we made our findings. This point is acknowledged by Gieffers et al. in their discussion of results. In fact, another report that recently appeared in the literature (  Read more

View all comments by Brian Balin


Related News: Perinatal Soup—Early Pathogen or Toxin Exposures Leave Brain Vulnerable

Comment by:  Paul Coleman, ARF Advisor
Submitted 22 February 2005 Posted 22 February 2005

My speculations about AD include the thought that AD has an extremely long presymptomatic period, which may extend into childhood. This is based on data such as the Braaks finding that 20 percent of people in their 20s have neurofibrillary tangles (NFT) and senile plaques (SP), though not meeting the criteria for AD. It is also based on our knowledge that NFT and SP represent only the most obvious of a sequence of more subtle changes in tau conformation and other post-translational modifications that certainly precede the formation of frank NFT; similarly for APP and Aβ, and SP.

Whether the metals and infectious agents mentioned in this news review are related to this sort of speculation is not at all certain. There are a number of subtle parameters that could be looked at that might be informative.

View all comments by Paul Coleman

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password  
*Confirm Password  
Remember my Login and Password?  

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2010 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad